Press Release

Targeted Sequencing Market to Grow with a CAGR of 11.02% through 2029

Rising technological advancements and innovation is expected to drive the Global Targeted Sequencing Market growth in the forecast period, 2025-2029.

 

According to TechSci Research report, “Targeted Sequencing Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029”, the Global Targeted Sequencing Market stood at USD 3.51 Billion in 2023 and is anticipated to grow with a CAGR of 11.02% in the forecast period, 2025-2029. Companion diagnostics, leveraging biomarker-based tests to inform treatment decisions, are increasingly prominent in the healthcare sector. Targeted sequencing plays a critical role in companion diagnostics by identifying biomarkers linked to drug response, treatment resistance, and disease progression. With the rise of personalized medicine, there is a growing demand for targeted sequencing-based companion diagnostics, especially in oncology, where accurate treatment selection is crucial for enhancing patient outcomes.

Growing investments in genomics research and development are fostering innovation in the targeted sequencing market. Governments, academic institutions, and private enterprises are dedicating significant resources to support genomics initiatives focused on unraveling the genetic underpinnings of diseases, uncovering new therapeutic targets, and advancing precision medicine. These investments are spurring technological progress, driving down sequencing costs, and broadening the range of applications for targeted sequencing across diverse fields, including pharmacogenomics, agricultural genomics, and microbial genomics.

 

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Targeted Sequencing Market

 

The Global Targeted Sequencing market is segmented into product type, target enrichment method, target capture type, end users, application, regional distribution, and company.

Based on the product type, the kits/panels and assays segment emerged as the dominant segment in the Global Targeted Sequencing Market in 2023. The increasing need for comprehensive genomic profiling in clinical diagnostics and precision medicine has led to the widespread acceptance of targeted sequencing panels and assays. These panels are meticulously crafted to pinpoint clinically significant genes, mutations, and biomarkers linked to various diseases such as cancer, genetic disorders, and infectious diseases. By concentrating on specific genomic regions of interest, targeted sequencing panels and assays facilitate the efficient identification of actionable variants, paving the way for personalized treatment approaches.

Progressions in sequencing chemistry, library preparation techniques, and bioinformatics algorithms have bolstered the sensitivity, specificity, and accuracy of targeted sequencing assays, further propelling their adoption in both research and clinical environments. These technological enhancements have empowered researchers to identify low-frequency mutations, rare genetic variants, and structural rearrangements with heightened confidence, broadening the applicability of targeted sequencing across a diverse array of applications.

Based on the Target Capture Type, the Targeted DNA Sequencing segment emerged as the dominant segment in the global targeted sequencing market in 2023. Targeted DNA Sequencing offers a highly focused and efficient approach to interrogating specific regions of interest within the genome. By selectively targeting known genomic regions, such as exons, promoters, or regulatory elements, researchers can achieve deep coverage and high-resolution sequencing data, facilitating the detection of genetic variations, mutations, and structural rearrangements with exceptional sensitivity and accuracy. Targeted DNA Sequencing is particularly well-suited for studying genetic diseases, cancer, and inherited disorders, where the identification of disease-causing mutations or biomarkers is crucial for diagnosis, prognosis, and treatment selection. By focusing sequencing efforts on relevant genomic regions associated with specific diseases or traits, Targeted DNA Sequencing enables researchers and clinicians to efficiently identify actionable variants and tailor personalized treatment strategies.

Based on the Application, the oncology segment emerged as the dominant segment in the global targeted sequencing market in 2023. targeted sequencing has revolutionized cancer genomics by enabling the comprehensive profiling of tumor genomes, transcriptomes, and epigenomes. By identifying somatic mutations, copy number variations, and gene fusions associated with cancer development and progression, targeted sequencing facilitates the identification of actionable biomarkers and therapeutic targets. This enables oncologists to personalize treatment strategies, select appropriate targeted therapies, and monitor treatment responses, leading to improved patient outcomes. Moreover, the growing demand for precision medicine in oncology has fueled the adoption of targeted sequencing-based companion diagnostics. These tests help identify predictive biomarkers, such as mutations in oncogenes or tumor suppressor genes, that can guide treatment decisions and predict responses to targeted therapies or immunotherapies.

North America emerged as the dominant region in the Global Targeted Sequencing Market in 2023, holding the largest market share. The presence of a highly developed healthcare ecosystem and favorable regulatory environment in North America has facilitated the adoption of targeted sequencing technologies in clinical diagnostics and personalized medicine. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and Health Canada, provide clear guidelines and frameworks for the development and approval of targeted sequencing-based diagnostic tests and companion diagnostics, fostering innovation and commercialization in the market. Additionally, North America benefits from a strong network of industry players, including sequencing technology providers, biotechnology companies, and diagnostic laboratories, which drive market growth through research collaborations, product development, and commercialization efforts. The region also attracts substantial investments in genomics research and healthcare innovation, further fueling the expansion of the targeted sequencing market.

 

Major companies operating in Global Targeted Sequencing Market are:

  • MGI Tech Co., Ltd
  • GENEWIZ Inc
  • Agilent Technologies, Inc.
  • Daicel Arbor Biosciences
  • Danaher Corporation
  • Illumina, Inc.
  • LGC Biosearch Technologies
  • Pacific Biosciences of California Inc
  • CD Genomics
  • F. Hoffmann-La Roche Ltd

 

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The global Targeted Sequencing market is poised for significant expansion in the forthcoming years. the increasing prevalence of genetic disorders and cancer cases worldwide has heightened the demand for personalized medicine, where targeted sequencing plays a crucial role in identifying specific genetic variations and guiding treatment decisions. Secondly, advancements in sequencing technologies, such as improved accuracy, reduced costs, and enhanced scalability, are making targeted sequencing more accessible and practical for a broader range of applications. Additionally, the rising adoption of targeted sequencing in clinical diagnostics and drug development processes is likely to contribute significantly to the market's growth trajectory in the coming years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

 

Targeted Sequencing Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, Segmented By Product Type (Kits/Panels and Assays, Instruments and Other), By Target Enrichment Method (Amplicon Sequencing, Hybridization Capture, and Others), By Target Capture Type (Targeted DNA Sequencing ,Targeted RNA Sequencing and others), By Application(Oncology, Infectious Diseases, Cardiovascular Diseases, Reproductive Health, Rare Diseases, Neurological Disorders, Hereditary Diseases, and Others), By End Users (Academic and Research Institution, Pharmaceutical and Biotech Companies, Diagnostic & Clinical Laboratories and Other), By Region, By Competition, 2019-2029F”, has evaluated the future growth potential of Global Targeted Sequencing Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Targeted Sequencing Market.

 

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com


Relevant News